ClinicalTrials.gg
WithdrawnNCT06646016EPICUpdated Dec 26, 2025

EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis

A Phase 2 interventional study of Methoxsalen and Infliximab in Immune-related Colitis, sponsored by Therakos LLC. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-26.

Sponsored by Therakos LLC · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Study Withdrawn by Sponsor prior to Enrollment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 2,049 studies in Melanoma with a site in United States — 243 open to participants now, 440 under way, 32 of them phase 3. Melanoma · United States.

Enrollment
1,704th of 1,749
0 · median 37
Started
2025
with 61 others
Phase 2
612 of 2,049
46 open now
Registered
1,941st of 2,049
by date

Among the 2,049 studies in Melanoma with a site in United States, this one is the 1,704th largest by enrollment of the 1,749 interventional ones that give a count, is one of 62 that started in 2025, is one of 612 in phase 2, and was the 1,941st registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

243 of the 2,049 studies in Melanoma with a site in United States are open now. Recruiting first, the newest first:

238 more — sign in →

All 243 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,049 studies in Melanoma with a site in United States, or all of them as a file.
02

Study summary

The photoactivating agent UVADEX (methoxsalen) is used in conjunction with extracorporeal photopheresis (ECP) as an immunomodulatory therapy approved for the treatment of cutaneous T-cell lymphoma. ECP involves collecting whole blood from the patient, separating white blood cells (WBCs) via centrifugation, combining them with UVADEX, and then exposing them to ultraviolet A (UVA) light. All blood components, including the treated WBCs, are then returned to the patient.

Immune Checkpoint inhibitor (ICI) therapy is used to treat different types of cancer, and one major side-effect of ICI therapy is immune-related colitis (ir-colitis). The main purpose of the study is to evaluate the efficacy of UVADEX in conjunction with ECP versus best available therapy (BAT) in participants with melanoma or NSCLC that suffer from ir-colitis with inadequate response to steroids.

03

Conditions studied

  • Immune-related Colitis

Keywords

  • Melanoma
  • Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants diagnosed with unresectable or melanoma or unresectable, advanced or metastatic NSCLC, who received ICI treatment with agents like anti-programmed death-1 (), anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4), and had shown a response to the treatment, based on having a complete response, partial response, or stable disease determined by (RECIST) 1.1 criteria.
  • Participants diagnosed with ir-colitis of at least Grade 2 severity based on American Society of Clinical Oncology (ASCO) Guidelines (diarrhea with an increase of ≥4 stools more than at baseline) with other causes of diarrhea and colitis ruled out.
  • Participants with endoscopy evidence of ir-colitis based on colonoscopy (modified Mayo Endoscopy Subscore of ≥2).
  • Participants with inadequate response to , defined as no improvement in ir-colitis after at least 72 hours of corticosteroid treatment, or relapse of ir-colitis during or after corticosteroid tapering.
  • Participants who have an (ECOG) performance status of 0 or 2.
  • Participants who may become pregnant must have a negative serum pregnancy test, agree to use effective methods during the study and for 30 days after the last treatment, and not be breastfeeding.
  • Participants whose sexual partner may become pregnant, must use condoms or other effective contraception, and avoid donating blood, semen, or sperm during the study and for 90 days after the last treatment.
  • Participants must agree to wear UVA-absorbing, wrap-around sunglasses and cover exposed skin or use a sunblock (sun protection factor [SPF] ≥ 15) for the 24-hour period following treatment with UVADEX, whether exposed to direct or indirect sunlight.

Exclusion criteria

Exclusion Criteria:

  • Presence of irAEs and other than ir-colitis, with severity grade > 2 based on ASCO guidelines.
  • Treatment of ir-colitis with any systemic therapy other than .
  • Concurrent conditions that might require treatment with corticosteroids ≥ 1 milligram per kilogram body weight per day (mg/kg BW/day) prednisone equivalent.
  • Concomitant treatment with any chemotherapy or targeted therapy for malignant melanoma, NSCLC, or other cancers.
  • Use of any agent within 5 half-lives of the study treatment.
  • to study interventions or procedures (UVADEX, the ECP procedure, infliximab, or vedolizumab).
  • Known allergic reaction to any component of the investigational agents, 8-methoxsalen (UVADEX), infliximab, or vedolizumab.
  • Presence of aphakia or history of light-sensitive diseases such as lupus erythematosus, porphyria cutanea tarda, erythropoietic protoporphyria, variegate porphyria, xeroderma pigmentosum, or albinism.
  • Inability to tolerate the fluid shift associated with the ECP procedure.
  • Positive test for (HIV).
  • Positive test for tuberculosis (blood test).
  • History of prior allogeneic bone marrow or solid organ transplantation.
  • Previous or current within the last 3 years, other than unresectable or melanoma or unresectable, advanced, or metastatic NSCLC treated with ICI. Exceptions include adequately treated basal or squamous cell skin cancer.

Note: Other Inclusion/Exclusion criteria also apply.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    UVADEX in conjunction with extracorporeal photopheresis

    Participants will receive UVADEX, in conjunction with ECP procedure twice weekly for four weeks and then every other week for 8 weeks during the 12-week treatment period according to the treatment schedule.

    Drug: Methoxsalen

  • Active comparator
    Best available therapy (BAT)

    Participants will receive either infliximab or vedolizumab as per the investigator's choice during the 12-week treatment period.

    Drug: Infliximab · Drug: Vedolizumab

Interventions

  • Sterile solution used in conjunction with photopheresis procedure.

    Also known as: UVADEX®, 20 micrograms per milliliter (mcg/mL)

  • Infliximab will be administered intravenously.

    Also known as: REMICADE®, INFLECTRA®, IXIFI®, RENFLEXIS®, AVSOLA®

  • Vedolizumab will be administered intravenously.

    Also known as: ENTYVIO®

06

What researchers measure

Primary outcomes

  1. Proportion of Participants with Remission of ir-colitis at End of Treatment

    Composite endpoint of remission measured by diarrhea frequency (CTCAE grade 0 or 1 at Week 12) and colonic mucosal endoscopy score (modified Mayo Score 0 or 1 at Week 13).

    Time frame: Week 12 (diarrhea frequency) / Week 13 (colonic mucosal endoscopy score)

Secondary outcomes

  1. Total Duration of Remission for ir-colitis Based on the Criteria for Diarrhea

    Duration of remission is the time from when diarrhea improves until the time it comes back (if it does).

    Time frame: Week 64

  2. Proportion of Participants with Complete Resolution of Diarrhea

    Complete resolution of diarrhea refers to normal stool frequency.

    Time frame: Week 12

  3. Proportion of Participants with Complete Resolution of Colonic Endoscopic Changes

    Complete resolution of colonic endoscopic changes refers to no signs of inflammation or damage in the colon.

    Time frame: Week 13

  4. Proportion of Participants with Corticosteroid-free Clinical Remission

    Corticosteroid-free clinical remission is assessed based on the absence of diarrhea and daily corticosteroid dose \<5 mg prednisolone or equivalent at week 12.

    Time frame: Week 12

  5. Changes in the Nancy Score

    The Nancy histological index comprises 3 histological items defining 5 grades of disease activity: Grade 0 is absence of significant histological disease; Grade 1 is chronic inflammatory infiltrate with no acute inflammatory infiltrate; Grade 2 is mildly active disease; Grade 3 is moderately active disease; and Grade 4 is severely active disease.

    Time frame: Week 13

  6. Proportion of Participants with Stool Calprotectin Level <150 micrograms per gram (μg/g)

    Time frame: Week 26

  7. Proportion of Participants with Complete Resolution of Other Symptoms of ir-colitis

    Time frame: Week 64

  8. Time to Complete Resolution of ir-colitis Based on Common Terminology Criteria for Adverse Events (CTCAE) Criteria for Colitis

    Time frame: Week 64

  9. Time to Complete Resolution of Other Specified Immune-related Adverse Events (irAEs) (other than ir-colitis)

    The other specified irAEs may include pruritis, rash, inflammatory dermatitis, esophagitis, gastritis, hepatitis, pneumonitis, arthritis, myositis, polymyalgia and nephritis.

    Time frame: Week 64

  10. Time to Complete Discontinuation of Systemic Corticosteroids for at least 1 Week

    This is the time taken by a participant to stop using systemic corticosteroids entirely for at least one week.

    Time frame: Week 12

  11. Progression Free Survival (PFS) for Melanoma and NSCLC

    The approximate time from the start of treatment until the first incidence of cancer worsening or participants dying due to any cause.

    Time frame: Week 64

  12. Overall Survival (OS)

    The approximate time from the start of treatment until death due to any cause.

    Time frame: Week 64

07

Study locations

1 site
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2025; primary completion for Feb 2026, 1 month later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2024
First posted
Oct 17, 2024
StartEst.
Dec 15, 2025
Primary completionEst.
Feb 6, 2026
CompletionEst.
Feb 19, 2027
Last update
Dec 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06646016
Lead sponsor
Therakos LLC
Responsible party
Sponsor
First posted
Oct 17, 2024
Start date
Dec 15, 2025 (estimated)
Primary completion
Feb 6, 2026 (estimated)
Completion
Feb 19, 2027 (estimated)
Last update
Dec 26, 2025

Study contacts

Clinical Team Leader
study director · Therakos LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methoxsalen

Start the discussion